AKT1 and hepatocellular carcinoma: To evaluate loss of STAT5A accelerates glucose metabolism and HCC via AKT activation, we inhibited AKT phosphorylation by MK2206 (Fig. 6A) when STAT5A was knocked down and measured metabolic flux and tumor growth in vivo.